Before its launch in 2020, the vision for a unified clinical research platform at 海角社区 was already taking shape, inspired by the need to better support clinician-scientists navigating the complexity of clinical trials in infectious diseases.
What followed was a strategic investment by MI4: $1 million over five years, followed by an additional $100,000 in year six, to build and sustain a platform designed to remove logistical hurdles and unlock clinical research potential across the 海角社区 ecosystem.
Today, under the leadership of Makeda Semret, MD, FRCP(C), Associate Professor in the Department of Medicine at the Faculty of Medicine and Health Sciences, 海角社区, the MI4- Clinical Research Platform (CRP) continues to strengthen its operational capacity, enabling high-quality, efficient, and increasingly collaborative clinical research, both nationally and internationally.
To better understand how the platform has evolved, we sat down with Dr. Semret to discuss its growth, impact, and future.
You stepped into the role of Platform Director about a year ago. How has MI4's support helped you strengthen or accelerate the Clinical Research Platform?
MI4 support has truly allowed us to move from what used to be a project-by-project model to a coordinated and highly functional clinical research platform. In our short lifespan, we have successfully completed 16 studies. We currently support, fully or partially, ten clinical studies, and are preparing to launch an additional five in the next few months.
To do this, we have really worked hard to harmonize our processes, share infrastructure and human resources across multiple, mostly hospital-based, clinical research projects, so our highly qualified personnel are fully engaged throughout a series of assignments. The principal investigators (PIs) find that the startup period for clinical studies has become much faster and certainly less painful than in the past, and they value the quality and consistency of the support they receive.
MI4-CRP now leads national infectious disease trials and coordinates global networks. Why does that matter - for Canada and for patients?
We certainly have the ambition and the expectation that our researchers can successfully take on leadership roles in national and coordinated global networks, whether or not these are hosted directly by us. If 海角社区 becomes a leading contributor to global health priorities鈥攆or example, in antimicrobial resistance, emerging infections 鈥� then our local patients, as well as all Canadian patients, could benefit from better care that will include faster access to novel therapies, diagnostics, and other interventions. I think it also improves our collective resilience in the face of future health threats. This vision relies on a strong ecosystem that begins with facilitating clinical trials. Without coordinated support, clinical researchers face significant logistical and administrative barriers just to start up a clinical study, sometimes delaying the actual research by a year or more. By bringing together logistical expertise, the platform allows investigators to focus on science and data analysis rather than the operational burden of conducting studies, ultimately enabling them to develop their curiosity and expand their ambitions.
Since taking on the role, what has been the greatest strength of the platform - and wat surprised you most about it?
The core CRP team is quite small, currently consisting of 2 research nurses, 2 research coordinators, a program manager, and part-time laboratory support staff. Their commitment and enthusiasm are the platform鈥檚 greatest strength. It is an expertise-based platform, built on know-how. I am constantly impressed by the team鈥檚 ability to support a wide range of complex studies across diverse clinical settings.
What surprised me most is how nimble the team is. They can quickly find solutions to daily challenges. As an initial process, we review a large number of proposals to determine whether we鈥檙e the right fit, whether we can deliver, and whether we have the right principal investigator and patient population. What鈥檚 really changed is that we can now do this quite rapidly and efficiently. The team also appreciates the fact that there is a delicate balance between predictable and stable work versus the excitement of new opportunities with new projects.
If you had to capture MI4-CRP's growth through this partnership in one sentence, what would it be?
I would say that the partnership with MI4 has allowed us to evolve from a collection of individuals conducting clinical studies in silos to a globally connected clinical research platform with the capacity to deliver and lead high-impact infectious disease trials. Without MI4鈥檚 initial support, the Clinical Research Platform would never have seen the light of day.
Before concluding, Dr. Semret reflected on the platform鈥檚 future with both ambition and caution:
鈥淭his platform is not guaranteed long-term sustainability. We need to nurture and grow it strategically 鈥� expanding thoughtfully, but at the same time avoiding scaling to a point where we compromise the quality of our work.鈥�
It is this balance between growth and excellence that continues to define the MI4 Clinical Research Platform today.
